NSC 74859 (S3I-201)

Catalog No.S1155 Batch:S115501

Print

Technical Data

Formula

C16H15NO7S

Molecular Weight 365.36 CAS No. 501919-59-1
Solubility (25°C)* In vitro DMSO 73 mg/mL (199.8 mM)
Ethanol 3 mg/mL (8.21 mM)
Water Insoluble
In vivo (Add solvents to the product individually and in order)
Homogeneous suspension
CMC-NA
≥5mg/ml Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description NSC 74859 (S3I-201) shows potent inhibition of STAT3 DNA-binding activity with IC50 of 86 μM in cell-free assays, and low activity towards STAT1 and STAT5.
Targets
STAT3 [1]
(Cell-free assay)
86 μM
In vitro

S3I-201 inhibits growth and induces apoptosis preferentially in tumor cells that contain persistently activated Stat3 by inhibiting Stat3·Stat3 complex formation and Stat3 DNA-binding and transcriptional activitie. Moreover, S3I-201 also inhibits the expression of the Stat3-regulated genes encoding cyclin D1, Bcl-xL, and survivin. [1] S3I-201 inhibits breast carcinoma MDA-MB-435, MDA-MB-453 and MDA-MB-231 cell lines with IC50 of 100 μM. In addition, the cells with impaired TGF-β signaling are four times as sensitive to the STAT3 inhibitor S3I-201. [2] A recent study shows that S3I-201 potentiates the antiproliferative effect in HepG2 and Huh-7 cells via the STAT3 signalling pathway. [3]

In vivo

S3I-201 (5 mg/kg, i.v. every 2 or every 3 days) shows the antitumor efficacy in mouse models with human breast tumor xenografts that harbor constitutively active Stat3. [1] S3I-201 treatment reduces Varicella-zoster virus (VZV) replication on the basis of the bioluminescence signal and the number of positive skin xenografts compared with DMSO-treated mice by inhibiting STAT3 phosphorylation. [4]

Features A chemical probe inhibitor of Stat3 activity.

Protocol (from reference)

Kinase Assay:

[1]

  • In vitro Stat3 DNA-binding assay and EMSA analysis

    Briefly, 100 mL of biotinyl-e-Ac-EPQpYEEIEL-OH (in 50 mM Tris/150 mM NaCl, pH 7.5) is added to each well of streptavidin-coated 96-well microtiter plates and incubated with shaking at 4 °C overnight. Then plates are rinsed with PBS/Tween 20 and then two times with 200 mL of BSA-T-PBS (0.2% BSA/0.1% Tween 20/PBS). Then 50 mL of Lck-SH2-GST fusion protein (6.4 ng/ml in BSA-T-PBS) is added to each well of the 96-well plate in the presence and absence of 50 mL of S3I-201 (for 30 and 100 mM final concentrations), and the plate is shaken at room temperature for 4 hours. After solutions are removed, each well is rinsed four times with BSA-T-PBS (200 mL), and 100 mL of polyclonal rabbit anti-GST antibody (100 ng/mL in BSA-T-PBS) is added to each well and incubated at 4 °C overnight. After washing with BSA-T-PBS, 100 mL of 200 ng/mL BSA-T-PBS horseradish peroxidase-conjugated mouse anti-rabbit antibody is added to each well and incubated for 45 minutes at room temperature. After four washing steps with BSA-T-PBS and three washing steps with PBS-T, 100 mL of peroxidase substrate is added to each well and incubated for 5-15 minutes. The peroxidase reaction is stopped by adding 100 mL of 1 M sulfuric acid solution, and absorbance is read at 450 nm with an ELISA plate rea

Cell Assay:

[2]

  • Cell lines

    MDA-MB-435, MDA-MB-453 and MDA-MB-231 cells lines

  • Concentrations

    ~ 250 μM

  • Incubation Time

    72 hours

  • Method

    The MTT assay is based on the conversion of the yellow tetrazolium salt MTT to purple formazan crystals by metabolically active cells. The MTT assay provides a quantitative determination of viable cells. Cells are seeded in 96-well microplates in complete culture medium in the absence or presence of increasing serial dosages of S3I-201 as indicated. At 72 hours after culture, the number of viable cells is measured by adding 100 μL/well of 2 mg/mL MTT solution. After 2 hours, the medium is removed. The absorbance is read at 590 nm with an enzyme-linked immunosorbent assay reader. Each treatment point is performed in 10 wells or sextuplicate.

Animal Study:

[1]

  • Animal Models

    Human breast cancer MDA-MB-231 cells are injected s.c. into the left flank of athymic nu/nu mice.

  • Dosages

    ≤5 mg/kg

  • Administration

    Administered via i.v.

References

  • https://pubmed.ncbi.nlm.nih.gov/17463090/
  • https://pubmed.ncbi.nlm.nih.gov/19137011/
  • https://pubmed.ncbi.nlm.nih.gov/22098470/
  • https://pubmed.ncbi.nlm.nih.gov/22190485/

Customer Product Validation

The inhibitors U0126, PP1 and S3I-201 reduce the colony-forming ability of KIF5B-RET positive cells. A549 cells carrying KIF5B-RET were diluted and seeded in 6-well plates, treated with DMSO, U0126 (MEK inhibitor) 10 uM, PP1 (SRC inhibitors) 5 uM or S3I-201(STAT3 inhibitors) 100 uM for 14 days. The total numbers of colonies, each containing more than 40 cells, were determined. (*P < 0.05, **P < 0.01, ***P < 0.001, Student

Data from [ Mol Cancer , 2014 , 13:176 ]

(A) The expression and phosphorylation of STAT3 in DCs after inhibition by NSC74859 was measured by western blot. β-Actin was measured as an internal control. The results are representative of three independent experiments. The expression of PD-L1 in DCs after STAT3 inhibition by NSC74859. DCs were seeded at a density of 2 x 10<sup>6</sup>per well in 6-well plates. NSC74859 (100 uM) and TGF-β (10 ng/ml) were added on day 4 of DC culture. Cells were harvested on day 6, and the expression of PD-L1 was analyzed by western blot and flow cytometry. (B) The expression of PD-L1 was measured by western blot. (C) Densitometric analysis from the above immunoblots is shown as a bar chart. Data are shown as the means ± SD from 3 replicate experiments. **P < 0.01 vs. control DCs; ##P < 0.01 vs. stimulated with TGF-β only.

Data from [ Int Immunopharmacol , 2014 , 20(1), 117-23 ]

The survival phenotype of A549 cells dependents on transiently activation of STAT3 signaling pathway. A549 cells were mock-invaded (A549, medium alone as control) following treatment with or without NSC 74859 for 24 h. DMSO was used for control. Cell lysates were analyzed by immunoblotting with antibodies to pSTAT3, STAT3 (2 h), and β-actin.

Data from [ Microbes Infect , 2014 , 16(1), 17-27 ]

On day 1, 5-week-old female NOD/SCID mice were injected with 1 x 10<sup>8</sup> cells of the NOD/SCID repopulating T315I BCR-ABL1-positive leukemia UPN1 cells. On day 2, these mice were treated with either vehicle (n = 6), vismodegib (20 mg/kg per os; q.d.; n = 6), ponatinib (30 mg/kg; q.d.; n = 6), vismodegib (20 mg/kg per os; q.d.) + ponatinib (30 mg/kg; q.d.; n = 6) for each group. On day 28, mice were sacrificed for evaluation. CD19-positive cells from peripheral blood from each mouse have been shown. Histopathologic analysis of the bone marrow cavity from each treated mouse with UPN1 transplantation. Similar results were obtained in 2 independent experiments. H&E, hematoxylin and eosin.

Data from [ Clin Cancer Res , 2013 , 19(6), 1422-32 ]

Selleck's NSC 74859 (S3I-201) Has Been Cited by 253 Publications

Cancer-associated fibroblast derived CXCL14 drives cisplatin chemoresistance by enhancing nucleotide excision repair in bladder cancer [ J Exp Clin Cancer Res, 2025, 44(1):265] PubMed: 40898244
Natural small molecule bergapten ameliorates rheumatoid arthritis by targeting STAT3 [ Pharmacol Res, 2025, 219:107878] PubMed: 40714303
Polarization of Vδ2 T cells to a Th2-like phenotype promotes plasmablast differentiation and possesses pro-fibrotic properties in IgG4-related disease [ Front Immunol, 2025, 16:1550405] PubMed: 40213561
SYT7 accelerates nasopharyngeal carcinoma progression via ALDH1A3-mediated STAT3 signaling activation [ Oncogenesis, 2025, 14(1):16] PubMed: 40346036
KLHL25-ACLY module functions as a switch in the fate determination of the differentiation of iTreg/Th17 [ Commun Biol, 2025, 8(1):471] PubMed: 40119138
Intrapleural dual blockade of IL-6 and PD-L1 reprograms CAF dynamics and the tumor microenvironment in lung cancer-associated malignant pleural effusion [ Respir Res, 2025, 26(1):180] PubMed: 40349069
Suberosin attenuates rheumatoid arthritis by repolarizing macrophages and inhibiting synovitis via the JAK/STAT signaling pathway [ Arthritis Res Ther, 2025, 27(1):12] PubMed: 39838477
Regulation of keratinocyte barrier function and inflammatory response by the EGFR-STAT3 Pathway: Potential therapeutic implications of osimertinib and afatinib [ Cytokine, 2025, 185:156802] PubMed: 39612655
Effect of Anti-S100A4 Monoclonal Antibody Treatment on Experimental Skin Fibrosis and Systemic Sclerosis-Specific Transcriptional Signatures in Human Skin [ Arthritis Rheumatol, 2024, 76(5):783-795] PubMed: 38108109
Augmented ERO1α upon mTORC1 activation induces ferroptosis resistance and tumor progression via upregulation of SLC7A11 [ J Exp Clin Cancer Res, 2024, 43(1):112] PubMed: 38610018

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.